Cancer Immunotherapy Conference features latest research on response, resistance, treatment
Share

NEW YORK — The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.

Cancer immunotherapeutics work by unleashing the power of a patient’s immune system to fight cancer the way it fights pathogens like viruses and bacteria. Immune checkpoint inhibitors such as pembrolizumab and nivolumab, as well as CAR T-cell therapy, have revolutionized cancer care in recent years by yielding dramatic, durable responses in patients who previously had few treatment options. However, such responses are seen in only a fraction of patients, and many patients develop resistance to these treatments. There is a need for continued research and innovation so that more patients may benefit from the promise of cancer immunotherapy.

“We have made extraordinary progress in cancer immunotherapy in the past decade — the number of immunotherapeutics increased almost five-fold and the number of cancer types that can be treated by at least one immunotherapeutic more than tripled,” said AACR President Elizabeth M. Jaffee, MD, co-chair of this year’s conference and deputy director

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD